Kaiser Permanente: COVID-19 Vaccine Generates Immune Response, Well Tolerated
July 15, 2020
July 15, 2020
SEATTLE, Washington, July 15 -- Kaiser Permanente issued the following news release:
An investigational vaccine designed to protect against COVID-19 was generally well tolerated and prompted neutralizing activity in healthy adults, according to interim results published in the New England Journal of Medicine. The lead author of the study, detailed in "A SARS-CoV-2 mRNA Vaccine -- Preliminary Report," is Lisa A. Jackson, MD, MPH, a senior investigator at Kaiser Permanente W . . .
An investigational vaccine designed to protect against COVID-19 was generally well tolerated and prompted neutralizing activity in healthy adults, according to interim results published in the New England Journal of Medicine. The lead author of the study, detailed in "A SARS-CoV-2 mRNA Vaccine -- Preliminary Report," is Lisa A. Jackson, MD, MPH, a senior investigator at Kaiser Permanente W . . .